Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer.
Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer.
复制标题
DOI：
10.1093/jjco/hyx037
复制
发表时间：
2017-05-01
影响因子：
2.4
通讯作者：
Aoki D
中科院分区：
文献类型：
--
作者：
Masuda K;Hirasawa A;Irie-Kunitomi H;Akahane T;Ueki A;Kobayashi Y;Yamagami W;Nomura H;Kataoka F;Tominaga E;Banno K;Susumu N;Aoki D
研究背景患者的病史和家族性癌症史是评估遗传性癌症风险的重要信息。我们为妇科癌症患者制作了一份自填式问卷。这项试点研究分析了这份问卷的有用性和符合社会妇科肿瘤标准的卵巢癌和子宫内膜癌patients.Methodovarian或子宫内膜癌患者的发病率。在获得知情同意后，参与者完成了调查问卷。根据妇科肿瘤学会指南，从每位患者的问卷调查数据中评估遗传风险。遗传风险groups.ResultsA共105例患者被确定为卵巢癌和56例子宫内膜癌符合本研究的临床和病理结果进行了比较。根据妇科肿瘤学会指南，在105例卵巢癌患者中，25例患者（23%）的遗传性乳腺癌和卵巢癌综合征风险为20-25%，3例患者（2.9%）的遗传性乳腺癌和卵巢癌综合征风险为5-10%。另外22名患者（21%）有5-10%的Lynch综合征风险。2例患者（1.9%）符合阿姆斯特丹标准II。在56例子宫内膜癌患者中，24例患者（42.9%）有5-10%的Lynch综合征风险。与Lynch综合征的遗传风险的子宫内膜癌患者在诊断时较年轻（平均年龄：47.79）相比，没有Lynch综合征的遗传风险的患者（平均年龄：57.91）。ConclusionsIn this study，我们能够表明，新设计的问卷是一个有用的工具，用于评估癌症家族史沿着与妇科肿瘤学会标准或阿姆斯特丹标准II。当考虑卵巢癌患者患Lynch综合征的风险时，收集第二和第三亲属的家族史是很重要的。
BackgroundA patient's medical history and familial cancer history are important information for assessing the risk of hereditary cancer. We have generated a self-administered questionnaire for patients with gynecologic cancer. This pilot study analyzed the usefulness of this questionnaire and the rates of patients that meet the Society of Gynecologic Oncology criteria in ovarian cancer and endometrial cancer patients.MethodOvarian or endometrial cancer patients were recruited for this study. After informed consent was obtained, participants completed the questionnaire. Genetic risks were assessed from the data of each patient's questionnaire by Society of Gynecologic Oncology guideline. Clinical and pathological findings were compared between the genetic risk groups.ResultsA total of 105 patients were identified with ovarian cancer and 56 patients with endometrial cancer eligible for this study. According to the Society of Gynecologic Oncology guideline, of the 105 ovarian cancer patients, 25 patients (23%) had a 20–25% risk and three patients (2.9%) had a 5–10% risk of hereditary breast and ovarian cancer syndrome. A further 22 patients (21%) had a 5–10% risk of Lynch syndrome. Two patients (1.9%) met the Amsterdam criteria II. Of 56 endometrial cancer patients, 24 patients (42.9%) had a 5–10% risk of Lynch syndrome. The endometrial cancer patients with genetic risk of Lynch syndrome were younger (mean age: 47.79) at diagnosis compared to patients without a genetic risk of Lynch syndrome (mean age: 57.91).ConclusionsIn this study, we were able to show that the newly designed questionnaire is a useful tool for evaluating cancer family history along with Society of Gynecologic Oncology criteria or Amsterdam criteria II. When considering the risk of Lynch syndrome for a patient with ovarian cancer, it is important to collect a second and third relative's family history.